Dry Eye

Clocking in for Workplace Eye Wellness Month means knowing the environmental factors contributing to a patient's dry eye.

Rachon, OD, FAAO, DipABO, details her SECO 2026 poster presentation, "Treatment of Stage 1 NK Secondary to Acoustic Neuroma Removal with Cryopreserved Amniotic Membrane."

According to a VSP Vision Care news release, 71% say they experience performance impacts due to screen-related visual discomfort, equating to nearly one full workday of lost productivity each week.

Tonk, MD, MBA, references updates from TFOS DEWS III that promote standardized screening tools.

Improved guidance on preservatives and allergens needed to ensure safety.

Key clinical trial data and PDUFA dates in early 2026 focus on treatments for dry eye, age-related macular degeneration, and rare eye diseases.

Telomere biology may link ocular aging and tissue dysfunction in the eye.

New drugs on the market and survey findings were among some of the top stories in dry eye from the past year.

Aldeyra met with the FDA on December 12, 2025, in which the FDA requested the company submit the CSR from the reproxalap dry eye disease field trial to the NDA.

The eye care providers authored an opinion article that has been published in "The Ocular Surface."

HUC1-394 is a peptide-based eye drop for dry eyes being developed by the company.

This year's conference brought eye care professionals insights, tips, and pearls.

Researchers performed a secondary analysis of the DREAM study data.

The latest updates on myopia management, contact lenses, and dry eye were discussed in Boston.

Dry eye disease is ubiquitous, with up to 20% of middle-aged patients estimated to have moderate to severe symptoms or searching for a treatment.

A focus on driver-based treatment provides a broader clinical framework for smarter, more personalized dry eye care.

Transforming care by integrating systemic, ocular, and emotional health can deliver personalized treatment and better outcomes.

Xiidra is a prescription eye drop used to treat the signs and symptoms of dry eye disease (DED) and works by targeting the source of inflammation.

Dry eye specialists weigh in on what role dry eye plays in their practices.

New findings confirm TearCare's long-term effectiveness for dry eye disease, showing significant patient improvements with minimal treatments over 2 years.

TearCare is associated with greater health utility over time but also resulted in significant cost savings compared with CsA.

Due to ubiquity, optometrists tend to undertreat patients with dry eye.

The solution was approved by the US Food and Drug Administration in late May 2025.

The expanded clinical suite at Stanton Optical will include keratography, optical coherence tomography, and personalized therapy options for patients with dry eye.

The tool is designed to help with the application of mono-dose, dry eye eye drop vials more easily and accurately.